trending Market Intelligence /marketintelligence/en/news-insights/trending/aidlmhacp2gfst1se2qkba2 content esgSubNav
In This List

Sanofi epilepsy drug banned during pregnancy by French regulator

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sanofi epilepsy drug banned during pregnancy by French regulator

French regulator ANSM has banned the use of Sanofi's epilepsy drug valproate during pregnancy, Reuters reported, citing a statement from the agency.

ANSM, the national agency for the safety of medicines and health products, said valproate should not be prescribed to women of child-bearing age, barring exceptional circumstances.

Valproate is marketed by Sanofi as Depakine, Depakote and Epilim and was linked to major birth defects in children of women exposed to the drug.

In April, the U.K.'s Medicines and Healthcare products Regulatory Agency similarly banned valproate prescriptions to women or girls of child-bearing potential, except for those in a pregnancy prevention program.